Pinealon side effects

What is known in people

Pinealon's human safety record is thin: ClinicalTrials.gov lists no Pinealon study,¹ and none of the 22 PubMed records found for it in October 2026 is a registered clinical trial.⁶¹ A few small Russian studies give the human data, including these three:

• 32 adults aged 41 to 83 (2015): participants had several chronic illnesses and organic brain syndrome in remission.² The study tested Pinealon and Vesugen.²
• 110 people of different ages (2016): the study compared carbon dioxide baths, hyperbaric oxygen, massage, and Vesugen plus Pinealon.³
• Male truck drivers with stress-related neurotic symptoms (2012): the best psychoemotional results came from Pinealon combined with Vesugen.⁴ The abstract does not say how many drivers were treated.⁴

None of these three abstracts gives side effect frequencies.²³⁴ They also leave out doses, routes and length of use, so no finding in them can be tied to an amount.²³⁴

Findings that may signal harm

These are the safety-relevant findings in the sources reviewed for this page, ordered from the strongest evidence level (people) to the weakest (cells):

• Lower blood stem cell markers, people (2015): in the 32-person study of Pinealon and Vesugen, the authors measured a fall in CD34+ blood-forming stem cell markers.² They described it as significant inhibition of blood cell formation; the abstract does not say which peptide caused it.²
• Pro-oxidant activity, people (2015): the same study found pro-oxidant activity, measured by chemiluminescence.²
• Behavior and motor changes, old rats (2011): rats given Pinealon before their carotid arteries were blocked showed reduced position-finding, motivational behavior and motor performance.⁸ Caspase-3, a cell-death enzyme, rose moderately in their brains.⁸
• Higher resting oxidant levels, cells (2008): short peptides including pinealon raised the resting level of reactive oxygen species inside cells, though the share of dead neurons fell.⁹ A 2011 study measured something different: under oxidative stress, Pinealon limited the buildup of those molecules in a dose-dependent way.¹⁰

Findings that suggest tolerability

• In the 110-person comparison, the authors rated massage and the two oligopeptide preparations, Vesugen and Pinealon, as the safest methods.³ They based this on biochemical and immune measures and on clinical condition.³
• That rating compares the peptides with the other methods in the same study.³ The abstract gives no event counts.³
• In the 2015 study, the authors reported that Pinealon and Vesugen did not change chromatin condensation, which they read as safety at the level of the genes, a property they said should be studied further.²

Warnings

• Not FDA-approved: an October 2026 search of FDA's approval data found no product with pinealon as an active ingredient, so FDA has not approved it as safe and effective for any use.¹¹
• Product quality: Health Canada says the injectable Pinealon products it seized had not been assessed for safety, efficacy and quality.⁵ It warns that unauthorized injectable drugs may cause infection and allergic reactions, interact with other medicines, contain contaminants that may not be listed on the label, or may not have been made or stored safely.⁵
• Unstudied groups: long-term safety, use in pregnancy, use in children and use with other medicines have not been studied.⁶¹
• Labels: in an August 2026 warning letter to one peptide seller, FDA said evidence from the seller's website showed its products were intended as drugs for human use, despite "for research use only" labels.¹²
• Athletes: WADA's class S0 bans at all times any substance not covered by the list's other sections that has no government approval for human therapeutic use.¹³ USADA says the 2027 list, in force January 1, 2027, names peptides in general in S0.¹⁴

How to read these reports

Much of the Pinealon research comes from the St. Petersburg Institute of Bioregulation and Gerontology and its partners.¹⁰⁹ The human studies were published in Russian, and only their English abstracts were reviewed for this page.²³⁴ The 2015 abstract reports 32 participants but lists 18 men and 12 women, which adds to 30.² A 2026 US review of therapeutic peptides in orthopedics, which mentions pinealon, noted a current lack of clinical trials for the peptides it covers.¹⁵ Until a registered trial reports adverse events by dose, the side effect profile of Pinealon remains unknown.¹

Related pages

The full Pinealon profile covers what studies report, the doses used in animal research and its regulatory status. See also Peptide safety basics and Peptide dosage basics.